Topical minoxidil: its use in treatment of male pattern baldness. 1988

M I Kulick
Department of Surgery, University of California Medical School, San Francisco.

This review outlines the findings associated with topical minoxidil use. Approximately one-third of the treated patients will obtain terminal hair growth using a 2 to 3% solution twice a day. Patients should receive treatment for a minimum of six months to evaluate the drug's efficacy. Factors associated with patients who obtained new hair growth include: a thinning versus absolute baldness, treatment initiated at a relatively younger age, and hair growth noted within three months. Following a positive growth response, there may be a reduction in new hair growth gained with minoxidil use for more than one year. Stopping the medication is associated with an exacerbation of hair loss. Currently, patients with hypertension, cardiovascular disease, or any serious systemic illness should be excluded from therapy. Patients should be monitored every four to six months, or sooner with any complaints. Initial evaluation should include monitoring of the blood pressure, pulse, electrocardiogram and serum lipid determinations.

UI MeSH Term Description Entries
D008297 Male Males
D008914 Minoxidil A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371) Loniten,Regaine,Rogaine,U 10858
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000506 Alopecia Areata Loss of scalp and body hair involving microscopically inflammatory patchy areas. Alopecia Circumscripta

Related Publications

M I Kulick
March 1987, Journal of the American Academy of Dermatology,
M I Kulick
May 1986, The American journal of the medical sciences,
M I Kulick
March 1991, Irish medical journal,
M I Kulick
August 1985, Journal of the American Academy of Dermatology,
M I Kulick
July 1987, Journal of the American Academy of Dermatology,
M I Kulick
July 1986, Journal of the American Academy of Dermatology,
M I Kulick
March 1987, Journal of the American Academy of Dermatology,
M I Kulick
January 1989, Clinical and experimental dermatology,
M I Kulick
June 1987, Lancet (London, England),
M I Kulick
September 1987, Lancet (London, England),
Copied contents to your clipboard!